FDA 483 - Nina Gentile M.D - May 27, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Nina Gentile M.D. in Philadelphia, a clinical investigator, revealed a significant issue regarding the timely reporting of serious adverse events (SAEs). The firm failed to conduct investigations in accordance with the investigational plan, specifically by not reporting two subjects' SAEs within the required timeframe as stipulated by the study protocol. This indicates a lapse in adherence to clinical trial protocols and patient safety reporting.
ID · 1beb7417-9745-45c1-aeb6-7934d5ab0c78